Clinical trial · Observational
Expression of Tumor Markers in Circulating Tumor Cells of Metastatic Hormone-sensitive Prostate Cancer
Development of a Prognostic Model for Metastatic Hormone-sensitive Prostate Cancer by Sequentially Analyzing the Expression of Tumor Markers in Circulating Tumor Cells
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
As prostate cancer progresses, tumor cells dissociate and enter the bloodstream. Considered a "liquid biopsy," these circulating tumor cells (CTC) can show how a patient's cancer evolves and responds to treatments. The purpose of this study is to determine whether sequentially analyzing the expression of tumor markers in circulating tumor cells in newly diagnosed metastatic hormone-sensitive prostate cancer patients can predict the outcome of these patients.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Blood drawing | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Single arm
- interventionNames
- Other: Blood drawing
Primary outcomes (1)
- measure
- time to castration-resistant prostate cancer
- timeFrame
- 3 years
Secondary outcomes (4)
- measure
- time to radiographic progression
- timeFrame
- 3 years
- measure
- time to prostate specific antigen (PSA) progression
- timeFrame
- 3 years
- measure
- time to prostate specific antigen (PSA) nadir
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: 1. Male patients; 2. 18 yrs and older, and 80 yrs and younger; 3. Histologically or cytologically proven prostate adenocarcinoma; 4. Imaging examinations including Emission Computed Tomography (ECT),Positron Emission Tomography (PET),Computed Tomography(CT)and Magnetic Resonance Imaging (MRI) revealed non-regional lymph node metastasis, bone metastasis, or visceral metastasis; 5. Not yet receiving hormonal therapy; 6. Not yet receiving chemotherapy previously; 7. Not yet receiving radical prostatectomy, radiotherapy, or transurethral resection of the prostate (TURP) previously; 8. Patients are willing to participate and can be followed up regularly； Exclusion Criteria: 1. Received radical prostatectomy, radiotherapy, or transurethral resection of the prostate (TURP) previously; 2. Received androgen deprivation therapy (including surgical castration, medical castration, anti-androgen therapy, and maximum androgen blockade) before inclusion; 3. Patients received chemotherapy previously; 4. Combined with other malignant tumor history (in addition to the skin basal cell carcinoma or other tumors that have been cured more than five years);
References
Publications (0)
Data not yet available